U.S. Markets closed

ResMed Inc. (RMD)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
70.07+0.02 (+0.03%)
At close: 4:02PM EDT
People also watch
VARCOOSTEBCRSTJ
Interactive chart
Previous Close70.05
Open69.96
Bid60.00 x 100
Ask75.22 x 200
Day's Range69.68 - 70.19
52 Week Range56.59 - 73.46
Volume238,324
Avg. Volume660,598
Market Cap9.94B
Beta0.81
PE Ratio (TTM)30.73
EPS (TTM)2.28
Earnings DateJul 26, 2017 - Jul 31, 2017
Dividend & Yield1.32 (1.88%)
Ex-Dividend Date2017-02-07
1y Target Est66.56
Trade prices are not sourced from all markets
  • Capital Cube2 days ago

    ETFs with exposure to ResMed, Inc. : May 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ResMed, Inc. Here are 5 ETFs with the largest exposure to RMD-US. Comparing the performance and risk of ResMed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Big Data Yields Big Insights for Treatment of Central Sleep Apnea
    PR Newswire6 days ago

    Big Data Yields Big Insights for Treatment of Central Sleep Apnea

    WASHINGTON, May 22, 2017 /PRNewswire/ -- According to a new ResMed-sponsored (NYSE:RMD) study, people with treatment-emergent central sleep apnea (CSA) have a significantly greater risk of terminating ...

  • Clinical Trial Published in JAMA Offers New Hope for COPD Patients
    PR Newswire7 days ago

    Clinical Trial Published in JAMA Offers New Hope for COPD Patients

    WASHINGTON, May 21, 2017 /PRNewswire/ -- People suffering from chronic obstructive pulmonary disease (COPD) – the third leading cause of death in the United States – may see their lives change thanks to a ResMed-sponsored clinical trial (RMD) presented at the 2017 American Thoracic Society International Conference and published in the Journal of the American Medical Association (JAMA) today. The trial, Home Oxygen Therapy - Home Mechanical Ventilation (HOT-HMV), was designed to investigate the effect of using non-invasive ventilation (NIV) at home on time to hospital readmission or death. Patients in the study had persistent hypercapnia (high levels of carbon dioxide in their blood) and had recently been hospitalized for a worsening of their COPD.